This company has been marked as potentially delisted and may not be actively trading. NASDAQ:LIFE aTyr Pharma (LIFE) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About aTyr Pharma Stock (NASDAQ:LIFE) 30 days 90 days 365 days Advanced Chart Get aTyr Pharma alerts:Sign Up Key Stats Today's Range N/A50-Day Range$1.57▼$2.0752-Week Range N/AVolume269,400 shsAverage Volume514,103 shsMarket Capitalization$131.12 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewaTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.Read More… Receive LIFE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for aTyr Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address LIFE Stock News HeadlinesVortex Energy Corp. Closes Listed Issuer Financing Exemption (LIFE) Private PlacementMay 22, 2025 | globenewswire.comaTyr Pharma, Inc. (ATYR): Analysts See 485% Upside PotentialMay 21, 2025 | insidermonkey.comTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... This is what President Trump said: "Our currency is crashing and will soon no longer be the world standard, which will be our greatest defeat, frankly, in 200 years." Why Would He Say This?May 28, 2025 | Augusta Precious Metals (Ad)Vortex Energy Corp. Announces Listed Issuer Financing Exemption (LIFE) Private PlacementApril 24, 2025 | globenewswire.comIs aTyr Pharma (ATYR) The Hot Biotech Stock Under $5?March 27, 2025 | insidermonkey.comaTyr Pharma (ATYR) Receives a Buy from Wells FargoMarch 18, 2025 | markets.businessinsider.comaTyr Pharma director buys $15K in common stockMarch 18, 2025 | markets.businessinsider.comaTyr Pharma’s Earnings Call Highlights Progress and ChallengesMarch 14, 2025 | tipranks.comSee More Headlines LIFE Stock Analysis - Frequently Asked Questions How were aTyr Pharma's earnings last quarter? aTyr Pharma, Inc. (NASDAQ:LIFE) released its quarterly earnings results on Thursday, May, 2nd. The biotechnology company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.01. The biotechnology company had revenue of $0.24 million for the quarter, compared to analyst estimates of $0.11 million. When did aTyr Pharma's stock split? Shares of aTyr Pharma reverse split on Monday, July 1st 2019. The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 28th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did aTyr Pharma IPO? aTyr Pharma (LIFE) raised $76 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Citigroup served as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers. What other stocks do shareholders of aTyr Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that aTyr Pharma investors own include Tesla (TSLA), Plug Power (PLUG), Meta Platforms (META), NVIDIA (NVDA), SCYNEXIS (SCYX), Ford Motor (F) and NIO (NIO). Company Calendar Last Earnings5/02/2024Today5/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:LIFE CIK1339970 Webwww.atyrpharma.com Phone(858) 731-8389Fax858-731-8394Employees56Year Founded2005Profitability EPS (Most Recent Fiscal Year)($0.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$50.39 million Net MarginsN/A Pretax Margin-9,172.11% Return on Equity-56.92% Return on Assets-43.87% Debt Debt-to-Equity Ratio0.02 Current Ratio6.07 Quick Ratio6.07 Sales & Book Value Annual Sales$350,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.54 per share Price / BookN/AMiscellaneous Outstanding Shares69,010,000Free Float66,458,000Market Cap$131.12 million OptionableOptionable Beta1.19 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:LIFE) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredTrump Quietly Planning $15 Trillion Crypto ShockerMost investors are still unaware, but I believe a new White House action may have quietly opened the floodgate...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding aTyr Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share aTyr Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.